MM-121: Phase II data

Merrimack disclosed on a conference call to discuss its 2Q13 earnings that a pre-specified interim analysis by a DSMB of an open-label, international Phase II trial in 223 patients with platinum-resistant or refractory advanced ovarian cancer showed that MM-121 plus paclitaxel would not meet the primary endpoint of improving PFS vs. paclitaxel alone in the overall population. Merrimack said it will continue the trial based on "expectations of the potential for subgroup benefit." The company expects to report final data this year. ...